Search research articles
Contact Us
Filters
Showing results (1-10 of 12) with videos related to
Page
of 2
Sort By:
BMC Research Notes
|
March 23, 2010
Analysing time course microarray data using Bioconductor: a case study using yeast2 Affymetrix arrays
Colin S Gillespie, Guiyuan Lei, Richard J Boys, et al.
Genome Biology
|
October 3, 2008
A genome wide analysis of the response to uncapped telomeres in budding yeast reveals a novel role for the NAD+ biosynthetic gene BNA2 in chromosome end protection
Amanda Greenall, Guiyuan Lei, Daniel C Swan, et al.
Blood
|
July 12, 2013
Obinutuzumab (GA101) plus CHOP or FC in relapsed/refractory follicular lymphoma: results of the GAUDI study (BO21000)
John Radford, Andrew Davies, Guillaume Cartron, et al.
Annals of the Rheumatic Diseases
|
June 13, 2012
Effect of baseline rheumatoid factor and anticitrullinated peptide antibody serotype on rituximab clinical response: a meta-analysis
John D Isaacs, Stanley B Cohen, Paul Emery, et al.
Haematologica
|
December 25, 2016
Safety and efficacy of obinutuzumab with CHOP or bendamustine in previously untreated follicular lymphoma
Andrew Grigg, Martin J S Dyer, Marcos González Díaz, et al.
BMJ Open
|
August 21, 2013
IL-6 pathway-driven investigation of response to IL-6 receptor inhibition in rheumatoid arthritis
Jianmei Wang, Adam Platt, Ruchi Upmanyu, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
July 10, 2013
Obinutuzumab (GA101) in patients with relapsed/refractory indolent non-Hodgkin lymphoma: results from the phase II GAUGUIN study
Gilles A Salles, Franck Morschhauser, Philippe Solal-Céligny, et al.
Blood
|
August 22, 2014
Obinutuzumab (GA101) in relapsed/refractory chronic lymphocytic leukemia: final data from the phase 1/2 GAUGUIN study
Guillaume Cartron, Sophie de Guibert, Marie-Sarah Dilhuydy, et al.
Breast Cancer Research and Treatment
|
June 22, 2020
Pertuzumab, trastuzumab, and docetaxel for Chinese patients with previously untreated HER2-positive locally recurrent or metastatic breast cancer (PUFFIN): a phase III, randomized, double-blind, placebo-controlled study
Binghe Xu, Wei Li, Qingyuan Zhang, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
July 10, 2013
Obinutuzumab (GA101) monotherapy in relapsed/refractory diffuse large b-cell lymphoma or mantle-cell lymphoma: results from the phase II GAUGUIN study
Franck Andre Morschhauser, Guillaume Cartron, Catherine Thieblemont, et al.
Page
of 2
Search research articles
Search
Showing results (1-10 of 12) with videos related to
Sort By:
Page
of 2
BMC Research Notes
|
March 23, 2010
Analysing time course microarray data using Bioconductor: a case study using yeast2 Affymetrix arrays
Colin S Gillespie, Guiyuan Lei, Richard J Boys, et al.
Genome Biology
|
October 3, 2008
A genome wide analysis of the response to uncapped telomeres in budding yeast reveals a novel role for the NAD+ biosynthetic gene BNA2 in chromosome end protection
Amanda Greenall, Guiyuan Lei, Daniel C Swan, et al.
Blood
|
July 12, 2013
Obinutuzumab (GA101) plus CHOP or FC in relapsed/refractory follicular lymphoma: results of the GAUDI study (BO21000)
John Radford, Andrew Davies, Guillaume Cartron, et al.
Annals of the Rheumatic Diseases
|
June 13, 2012
Effect of baseline rheumatoid factor and anticitrullinated peptide antibody serotype on rituximab clinical response: a meta-analysis
John D Isaacs, Stanley B Cohen, Paul Emery, et al.
Haematologica
|
December 25, 2016
Safety and efficacy of obinutuzumab with CHOP or bendamustine in previously untreated follicular lymphoma
Andrew Grigg, Martin J S Dyer, Marcos González Díaz, et al.
BMJ Open
|
August 21, 2013
IL-6 pathway-driven investigation of response to IL-6 receptor inhibition in rheumatoid arthritis
Jianmei Wang, Adam Platt, Ruchi Upmanyu, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
July 10, 2013
Obinutuzumab (GA101) in patients with relapsed/refractory indolent non-Hodgkin lymphoma: results from the phase II GAUGUIN study
Gilles A Salles, Franck Morschhauser, Philippe Solal-Céligny, et al.
Blood
|
August 22, 2014
Obinutuzumab (GA101) in relapsed/refractory chronic lymphocytic leukemia: final data from the phase 1/2 GAUGUIN study
Guillaume Cartron, Sophie de Guibert, Marie-Sarah Dilhuydy, et al.
Breast Cancer Research and Treatment
|
June 22, 2020
Pertuzumab, trastuzumab, and docetaxel for Chinese patients with previously untreated HER2-positive locally recurrent or metastatic breast cancer (PUFFIN): a phase III, randomized, double-blind, placebo-controlled study
Binghe Xu, Wei Li, Qingyuan Zhang, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
July 10, 2013
Obinutuzumab (GA101) monotherapy in relapsed/refractory diffuse large b-cell lymphoma or mantle-cell lymphoma: results from the phase II GAUGUIN study
Franck Andre Morschhauser, Guillaume Cartron, Catherine Thieblemont, et al.
Page
of 2